Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Getein BiotechSHSE:603387 +2.18%77 EBITDA Margin % is 31.16% as of Mar. 2026, which is 16% below its 10-year median of 36.91. GuruFocus rates SHSE:603387 with a GF Score™ of 77/100 and a GF Value™ of ¥7.57 (Modestly Overvalued). The stock has 2 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Getein Biotech ranks better than 81.62% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Getein Biotech's EBITDA for the
three
months ended in Mar. 2026 was ¥83 Mil. Getein Biotech's Revenue for the
three
months ended in Mar. 2026 was ¥268 Mil. Therefore, Getein Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was 31.16%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Getein Biotech EBITDA Margin % Related Terms
Getein Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Getein Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:603387 vs ABT, SYK, MDT: EBITDA Margin % Comparison
For the Medical Devices subindustry, Getein Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Getein Biotech EBITDA Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Getein Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Getein Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Getein Biotech (SHSE:603387) has a EBITDA Margin % of 31.16% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Getein Biotech and its competitors. This is 16% below median its historical median of 36.91. Over the past decade, Getein Biotech's EBITDA Margin % has ranged from 23.43 to 48.41. According to the industry distribution chart, Getein Biotech ranks #150 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 18.4%.
Is Getein Biotech's EBITDA Margin % too high?
Getein Biotech's current EBITDA Margin % of 31.16% is 16% below median its 10-year median of 36.91. Over the past 10 years, this metric has ranged from a low of 23.43 to a high of 48.41. The Medical Devices & Instruments industry median EBITDA Margin % is 7.52. Getein Biotech's value of 31.16% is 314.4% above this industry median. Based on the distribution chart, Getein Biotech ranks #150 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Getein Biotech has a GF Score™ of 77/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Getein Biotech's EBITDA Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Getein Biotech ranks #150 out of 816 companies for EBITDA Margin %. This places Getein Biotech in the top 18% of its industry — outperforming the majority of peers. The industry median EBITDA Margin % is 7.52. Getein Biotech's value of 31.16% is 314.4% above this benchmark. Historically, Getein Biotech's own EBITDA Margin % has ranged from 23.43 to 48.41 over the past decade. While the company's 10-year median is 36.91 vs. the industry median of 7.52, Getein Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Devices & Instruments company?
The median EBITDA Margin % among Medical Devices & Instruments companies is 7.52, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Getein Biotech's current EBITDA Margin % of 31.16% is 314.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Getein Biotech and its competitors. For the Medical Devices & Instruments industry, the median EBITDA Margin % is 7.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Getein Biotech's current EBITDA Margin % is 31.16%, which is 16% below median its own 10-year median of 36.91. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Getein Biotech stock overvalued right now?
Based on GuruFocus' analysis, Getein Biotech (SHSE:603387) is currently considered Modestly Overvalued. The stock's GF Value™ is ¥7.57, compared to a current price of ¥8.90 — trading 17.6% above its estimated fair value. The current EBITDA Margin % is 31.16%, which is 16% below median its 10-year median of 36.91 and 314.4% above the Medical Devices & Instruments industry median of 7.52. Getein Biotech's overall GF Score™ is 77/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Getein Biotech (SHSE:603387), the current EBITDA Margin % is 31.16% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Getein Biotech (SHSE:603387) Overvalued in 2026?
Based on GuruFocus' analysis, Getein Biotech stock appears to be overvalued.
The current stock price of ¥8.90 is trading 17.6% above its estimated GF Value™ of ¥7.57.
GuruFocus considers Getein Biotech to be Modestly Overvalued.
Key valuation signals for SHSE:603387:
EBITDA Margin %: 31.16% (16% below median its 10-year median of 36.91)
GF Value™: ¥7.57 vs. price of ¥8.90 (17.6% above fair value)
Industry Position: 314.4% above the Medical Devices & Instruments median (#150 of 816)
No single metric tells the full story. See the SHSE:603387 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Getein Biotech Inc is an in-vitro diagnostic company. It is specializing in analytical medical devices and point-of-care testing kits. Its product lines consist of cardiovascular, inflammatory, diabetes, fertility, renal, liver and specialty assays.
77GF Score
Get the complete analysis for SHSE:603387
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603387 has been successfully added to your 
